Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF.

Hepatology. 2019 May 7. doi: 10.1002/hep.30699. [Epub ahead of print]

PMID:
31062385
2.

Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection.

Jalal PJ, King BJ, Saeed A, Adedeji Y, Mason CP, Ball JK, Irving WL, McClure CP, Tarr AW.

Virology. 2019 Apr;530:99-106. doi: 10.1016/j.virol.2019.02.002. Epub 2019 Feb 12.

PMID:
30798068
3.

Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.

Merat SJ, Bru C, van de Berg D, Molenkamp R, Tarr AW, Koekkoek S, Kootstra NA, Prins M, Ball JK, Bakker AQ, de Jong MD, Spits H, Beaumont T, Schinkel J.

J Hepatol. 2019 Jul;71(1):14-24. doi: 10.1016/j.jhep.2019.02.013. Epub 2019 Feb 21.

PMID:
30797052
4.

Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses.

Jalal PJ, Urbanowicz RA, Horncastle E, Pathak M, Goddard C, Saeed A, Mason CP, Ball JK, Irving WL, McClure CP, King BJ, Tarr AW.

J Med Microbiol. 2019 Apr;68(4):642-648. doi: 10.1099/jmm.0.000935. Epub 2019 Feb 12.

PMID:
30747617
5.

Shared Common Ancestry of Rodent Alphacoronaviruses Sampled Globally.

Tsoleridis T, Chappell JG, Onianwa O, Marston DA, Fooks AR, Monchatre-Leroy E, Umhang G, Müller MA, Drexler JF, Drosten C, Tarlinton RE, McClure CP, Holmes EC, Ball JK.

Viruses. 2019 Jan 30;11(2). pii: E125. doi: 10.3390/v11020125.

6.

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR.

J Virol. 2019 Mar 21;93(7). pii: e01403-18. doi: 10.1128/JVI.01403-18. Print 2019 Apr 1.

7.

Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).

Bailey JR, Urbanowicz RA, Ball JK, Law M, Foung SKH.

Methods Mol Biol. 2019;1911:441-450. doi: 10.1007/978-1-4939-8976-8_30.

8.

Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins.

Urbanowicz RA, Ball JK, Tarr AW.

Methods Mol Biol. 2019;1911:275-294. doi: 10.1007/978-1-4939-8976-8_19.

PMID:
30593633
9.

InFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular Clones.

King B, Urbanowicz R, Tarr AW, Ball JK, McClure CP.

Methods Mol Biol. 2019;1911:93-104. doi: 10.1007/978-1-4939-8976-8_6.

PMID:
30593620
10.

Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.

Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP, Ball JK.

Antiviral Res. 2018 Dec;160:25-37. doi: 10.1016/j.antiviral.2018.09.005. Epub 2018 Sep 11.

PMID:
30217650
11.

Trichodysplasia Spinulosa Polyomavirus in Respiratory Tract of Immunocompromised Child.

Bagasi AA, Khandaker T, Clark G, Akagha T, Ball JK, Irving WL, McClure CP.

Emerg Infect Dis. 2018 Sep;24(9):1744-1746. doi: 10.3201/eid2409.180829.

12.

Human Adaptation of Ebola Virus during the West African Outbreak.

Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK.

Cell. 2016 Nov 3;167(4):1079-1087.e5. doi: 10.1016/j.cell.2016.10.013.

13.

Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.

Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF.

Hepatology. 2016 Nov;64(5):1495-1506. doi: 10.1002/hep.28767. Epub 2016 Sep 30.

PMID:
27531416
14.

Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.

Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK, Tarr AW.

J Gen Virol. 2016 Sep;97(9):2265-79. doi: 10.1099/jgv.0.000537. Epub 2016 Jul 6.

15.

Flexible and rapid construction of viral chimeras applied to hepatitis C virus.

McClure CP, Urbanowicz RA, King BJ, Cano-Crespo S, Tarr AW, Ball JK.

J Gen Virol. 2016 Sep;97(9):2187-93. doi: 10.1099/jgv.0.000530. Epub 2016 Jun 21.

16.

Discovery of Novel Alphacoronaviruses in European Rodents and Shrews.

Tsoleridis T, Onianwa O, Horncastle E, Dayman E, Zhu M, Danjittrong T, Wachtl M, Behnke JM, Chapman S, Strong V, Dobbs P, Ball JK, Tarlinton RE, McClure CP.

Viruses. 2016 Mar 18;8(3):84. doi: 10.3390/v8030084.

17.

Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.

Ferns RB, Tarr AW, Hue S, Urbanowicz RA, McClure CP, Gilson R, Ball JK, Nastouli E, Garson JA, Pillay D.

Virology. 2016 May;492:213-24. doi: 10.1016/j.virol.2016.02.003. Epub 2016 Mar 21.

18.

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA, Krey T, Irving WL, Ball JK, Tarr AW.

J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.

19.

An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule.

Nigro E, Colavita I, Sarnataro D, Scudiero O, Zambrano G, Granata V, Daniele A, Carotenuto A, Galdiero S, Folliero V, Galdiero M, Urbanowicz RA, Ball JK, Salvatore F, Pessi A.

Sci Rep. 2015 Dec 21;5:18450. doi: 10.1038/srep18450.

20.

Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C.

J Gen Virol. 2016 Jan;97(1):82-94. doi: 10.1099/jgv.0.000330. Epub 2015 Oct 29.

21.

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.

Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P.

Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045. Epub 2015 Aug 25.

PMID:
26306759
22.

Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.

Urbanowicz RA, Lacek K, Lahm A, Bienkowska-Szewczyk K, Ball JK, Nicosia A, Cortese R, Pessi A.

J Pept Sci. 2015 Sep;21(9):743-9. doi: 10.1002/psc.2802.

PMID:
26292842
23.

Non-ionic detergents facilitate non-specific binding of M13 bacteriophage to polystyrene surfaces.

Hakami AR, Ball JK, Tarr AW.

J Virol Methods. 2015 Sep 1;221:1-8. doi: 10.1016/j.jviromet.2015.04.023. Epub 2015 Apr 27.

PMID:
25929990
24.

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T.

J Virol. 2015 Feb;89(4):2170-81. doi: 10.1128/JVI.02190-14. Epub 2014 Dec 3.

25.

Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A.

J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.

26.

Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.

Irving WL, Rupp D, McClure CP, Than LM, Titman A, Ball JK, Steinmann E, Bartenschlager R, Pietschmann T, Brown RJ.

Antiviral Res. 2014 Oct;110:52-9. doi: 10.1016/j.antiviral.2014.07.009. Epub 2014 Jul 22.

PMID:
25057759
27.

Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, Irving WL, Ball JK, Harris M, Hickling TP, Tarr AW.

J Innate Immun. 2014;6(5):676-84. doi: 10.1159/000362209. Epub 2014 May 15.

28.

The past, present and future of neutralizing antibodies for hepatitis C virus.

Ball JK, Tarr AW, McKeating JA.

Antiviral Res. 2014 May;105:100-11. doi: 10.1016/j.antiviral.2014.02.013. Epub 2014 Feb 26. Review.

29.

Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution.

Brown RJ, Koutsoudakis G, Urbanowicz RA, Mirza D, Ginkel C, Riebesehl N, Calland N, Albecka A, Price L, Hudson N, Descamps V, Backx M, McClure CP, Duverlie G, Pecheur EI, Dubuisson J, Perez-del-Pulgar S, Forns X, Steinmann E, Tarr AW, Pietschmann T, Ball JK.

J Virol. 2014 Jan;88(1):667-78. doi: 10.1128/JVI.01745-13. Epub 2013 Oct 30.

30.

Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies.

Edwards VC, McClure CP, Brown RJ, Thompson E, Irving WL, Ball JK.

J Gen Virol. 2014 Jan;95(Pt 1):66-70. doi: 10.1099/vir.0.057828-0. Epub 2013 Oct 7.

31.

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.

Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T.

Hepatology. 2013 Sep;58(3):932-9. doi: 10.1002/hep.26430. Epub 2013 Jul 30.

PMID:
23553604
32.

HIV-1 co-receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic.

McClure CP, Bowman CA, Geary I, Ryan C, Ball JK, Eley A.

HIV Med. 2013 Feb;14(2):108-14. doi: 10.1111/hiv.12002. Epub 2012 Nov 22.

33.

Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.

Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J, Zhu LF, Law M, Kneteman N, Tyrrell DL, McKeating JA, Ball JK.

J Virol. 2012 Nov;86(22):11956-66. doi: 10.1128/JVI.01079-12. Epub 2012 Aug 1.

34.

The role of humoral innate immunity in hepatitis C virus infection.

Tarr AW, Urbanowicz RA, Ball JK.

Viruses. 2012 Jan;4(1):1-27. doi: 10.3390/v4010001. Epub 2012 Jan 5. Review.

35.

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.

Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, Ball JK.

J Virol. 2012 Mar;86(5):2739-49. doi: 10.1128/JVI.06492-11. Epub 2011 Dec 14.

36.

The role of neutralizing antibodies in hepatitis C virus infection.

Edwards VC, Tarr AW, Urbanowicz RA, Ball JK.

J Gen Virol. 2012 Jan;93(Pt 1):1-19. doi: 10.1099/vir.0.035956-0. Epub 2011 Nov 2. Review.

PMID:
22049091
37.

Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS.

J Virol. 2011 Jul;85(14):7005-19. doi: 10.1128/JVI.00586-11. Epub 2011 May 4.

38.

Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Brown RJ, Peters PJ, Caron C, Gonzalez-Perez MP, Stones L, Ankghuambom C, Pondei K, McClure CP, Alemnji G, Taylor S, Sharp PM, Clapham PR, Ball JK.

J Virol. 2011 Jun;85(12):6024-37. doi: 10.1128/JVI.00131-11. Epub 2011 Apr 6.

39.

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Tarr AW, Urbanowicz RA, Hamed MR, Albecka A, McClure CP, Brown RJ, Irving WL, Dubuisson J, Ball JK.

J Virol. 2011 May;85(9):4246-57. doi: 10.1128/JVI.01332-10. Epub 2011 Feb 16.

40.

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, Sim RB, Tarr AW, Hickling TP.

Protein Cell. 2010 Jul;1(7):664-74. doi: 10.1007/s13238-010-0088-9. Epub 2010 Jul 29.

41.

A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR.

J Virol. 2011 Mar;85(5):2397-405. doi: 10.1128/JVI.02187-10. Epub 2010 Dec 15.

42.

Identification of new functional regions in hepatitis C virus envelope glycoprotein E2.

Albecka A, Montserret R, Krey T, Tarr AW, Diesis E, Ball JK, Descamps V, Duverlie G, Rey F, Penin F, Dubuisson J.

J Virol. 2011 Feb;85(4):1777-92. doi: 10.1128/JVI.02170-10. Epub 2010 Dec 8.

43.

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Mancini N, Diotti RA, Perotti M, Sautto G, Clementi N, Nitti G, Patel AH, Ball JK, Clementi M, Burioni R.

PLoS One. 2009 Dec 11;4(12):e8254. doi: 10.1371/journal.pone.0008254.

44.

Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A.

J Virol. 2010 Jan;84(1):34-43. doi: 10.1128/JVI.02199-08.

45.

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.

46.

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.

J Gen Virol. 2008 Mar;89(Pt 3):653-9. doi: 10.1099/vir.0.83386-0.

47.

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

Hamed MR, Tarr AW, McClure CP, Ball JK, Hickling TP, Irving WL.

J Viral Hepat. 2008 May;15(5):339-45. doi: 10.1111/j.1365-2893.2007.00947.x. Epub 2008 Jan 22.

PMID:
18221305
48.

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR.

Nat Med. 2008 Jan;14(1):25-7. Epub 2007 Dec 6.

PMID:
18064037
49.

Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies.

Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK.

Curr Top Microbiol Immunol. 2008;317:1-38. Review.

PMID:
17990788
50.

Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R.

J Virol. 2008 Jan;82(2):1047-52. Epub 2007 Nov 7.

Supplemental Content

Support Center